研究者らは、がん治療に用いられるCAR-T細胞の製造効率を高めるため、リンパ節を模倣した3Dプリントゲルを開発した。この手法は従来の方法と比較して成功率を向上させ、細胞の増殖速度を速めることに成功した。これにより、コストの削減と世界中での治療アクセスの拡大が期待される。
CAR-T細胞の一般的な製造工程では、患者からT細胞を採取し、ウイルスを用いてがんを標的とするよう遺伝子改変を施した後、数週間かけて細胞を増殖させる必要がある。この工程には1回あたり28万ポンド以上の費用がかかる場合があり、完了までに最大で1ヶ月を要することも多いため、特に低所得国における治療の普及を妨げる要因となっている。
AIによるレポート AIによって生成された画像
A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.
Researchers have found that making cancer cells stiffer can enhance the effectiveness of car t-cell therapy against aggressive tumors. In experiments with mice, the approach led to complete tumor disappearance in some cases. The findings were presented recently at a conference in London.
AIによるレポート
A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.
Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.
AIによるレポート
Scientists at McMaster University and the Hospital for Sick Children in Canada have discovered that oligodendrocytes, cells typically supporting nerve function, aid the growth of glioblastoma by sending signals to tumor cells. Blocking this communication slowed tumor progression in lab models. The findings suggest an existing HIV drug, Maraviroc, could be repurposed for treatment.